Management of Low-Risk Prostate Cancer

Risk Classification and Active Surveillance

The European Association of Urology recommends active surveillance as the primary management strategy for patients with low-risk prostate cancer, defined as clinical stage T1-T2a, Gleason score ≤6, and PSA <10 ng/mL 1, 2
Low-risk prostate cancer is characterized by a Gleason score ≤6 (ISUP grade group 1) and PSA <10 ng/mL, according to the National Comprehensive Cancer Network 2
Very low-risk prostate cancer includes additional criteria such as clinical stage T1c, presence of disease in fewer than 3 biopsy cores, ≤50% prostate cancer involvement in any core, and PSA density <0.15 ng/mL/g 2

The National Comprehensive Cancer Network recommends PSA testing every 3-6 months, digital rectal examination every 6-12 months, and MRI before confirmatory biopsy if not performed before initial biopsy 1, 3
Confirmatory biopsy within 6-12 months of diagnosis is recommended, including both targeted biopsy and systematic biopsy 1, 3
Repeat biopsies at least once every 3 years for 10 years are recommended, with more rigorous follow-up for younger men 1, 3

The European Urology guidelines suggest considering switching to active treatment if there is PSA progression, change in DRE or MRI findings, or biopsy showing primary Gleason grade 4 or 5, greater number of positive cores, or greater extent of cancer in cores 1, 3
A PSA doubling time <3 years is also an indication for intervention, according to the National Comprehensive Cancer Network 3

The American Family Physician reports that prostate cancer-specific mortality is only 2.4% at 10 years for low-risk patients on active surveillance 4, 5
Treatment is associated with urinary, sexual, and bowel dysfunction, while only enhancing quality-adjusted survival of low-risk patients by 1.2 months 4, 5

The European Urology guidelines recommend considering radical prostatectomy only for patients with life expectancy >10 years, and associate it with higher rates of erectile dysfunction and urinary leakage 1, 2, 6
Radiation therapy, including external beam radiation therapy and brachytherapy, is a viable option for low-risk patients, with brachytherapy being an option for monotherapy 4, 6

Overtreatment is a common issue, with about 55% of low-risk patients receiving unnecessary treatment, according to the American Family Physician 4, 5
Provider bias and patient misunderstanding can also lead to inappropriate treatment decisions 4, 5
Inadequate monitoring and inappropriate patient selection can lead to missed progression or unnecessary biopsies 1, 7

Watchful waiting is appropriate for patients with life expectancy <10 years, according to the European Urology guidelines 1, 2
Patients should be informed that active surveillance maintains the window of curability while avoiding treatment side effects, as reported by the American Family Physician and European Urology Oncology 4, 7

The 5-year biochemical recurrence-free progression probability after radical prostatectomy for Grade Group 1 is 96% (95% CI, 95-96%), demonstrating that true Gleason 6 disease rarely progresses, according to the National Comprehensive Cancer Network 8

Very low-risk criteria include: T1c stage, Gleason score 6, PSA <10 ng/mL, <3 biopsy cores positive, ≤50% cancer in each core, and PSA density <0.15 ng/mL/g, as defined by the National Comprehensive Cancer Network 9
Patients meeting very low-risk criteria with life expectancy >20 years are recommended for active surveillance as the primary management strategy, as suggested by the National Comprehensive Cancer Network 9